{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:33:57Z","timestamp":1784810037786,"version":"3.55.0"},"reference-count":39,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>The objective of this study was to assess the in vitro activity of ceftaroline and a panel of comparator agents against isolates causing skin and soft tissue infections (SSTIs) collected in Africa\/Middle East, Asia\u2013Pacific, Europe, and Latin America from 2019\u20132020. Minimum inhibitory concentrations (MIC) were determined using European Committee on Antimicrobial Susceptibility Testing criteria. All the methicillin-susceptible Staphylococcus aureus (MSSA) isolates were susceptible to ceftaroline. Across all regions, ceftaroline demonstrated potent activity against methicillin-resistant S. aureus (MRSA, susceptibility 89.5\u201393.7%) isolates. Susceptibility to vancomycin, daptomycin, linezolid, teicoplanin, trimethoprim sulfamethoxazole, and tigecycline was \u226594.1% in MSSA and MRSA isolates. Against \u03b2-hemolytic streptococci isolates, ceftaroline demonstrated very potent activity (MIC90 0.008\u20130.03 mg\/L) across all regions. All \u03b2-hemolytic streptococci isolates were susceptible to linezolid, penicillin, and vancomycin (MIC90 0.06\u20132 mg\/L). Among the extended-spectrum \u03b2-lactamases (ESBL)-negative Enterobacterales tested (E. coli, K. pneumoniae, and K. oxytoca), susceptibility to ceftaroline was high (88.2\u201398.6%) in all regions. All ESBL-negative Enterobacterales were susceptible to aztreonam. Potent activity was observed for amikacin, cefepime, and meropenem (94.1\u2013100%) against these isolates. Overall, ceftaroline showed potent in vitro activity against isolates of pathogens causing SSTIs. Continuous surveillance of global and regional susceptibility patterns is needed to guide appropriate treatment options against these pathogens.<\/jats:p>","DOI":"10.3390\/antibiotics12081237","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T01:27:46Z","timestamp":1690421266000},"page":"1237","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["In Vitro Activity of Ceftaroline and Comparators against Bacterial Isolates Collected Globally from Patients with Skin and Soft Tissue Infections: ATLAS Program 2019\u20132020"],"prefix":"10.3390","volume":"12","author":[{"given":"Alona","family":"Kuraieva","sequence":"first","affiliation":[{"name":"Pfizer Inc., 66 Hudson Blvd. E., New York, NY 10001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4116-4736","authenticated-orcid":false,"given":"Guillermo","family":"Cabezas-Camarero","sequence":"additional","affiliation":[{"name":"Pfizer SLU, 28103 Alcobendas, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pattarachai","family":"Kiratisin","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2811-3069","authenticated-orcid":false,"given":"Eric","family":"Utt","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Groton, CT 06340, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1128\/microbiolspec.DMIH2-0014-2015","article-title":"Skin and Soft Tissue Infections","volume":"4","author":"Moffarah","year":"2016","journal-title":"Microbiol. Spectr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1468-3083.2011.04416.x","article-title":"Bacterial skin and soft tissue infections: Review of the epidemiology, microbiology, aetiopathogenesis and treatment: A collaboration between dermatologists and infectivologists","volume":"26","author":"Tognetti","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"iv2","DOI":"10.1093\/jac\/dkab350","article-title":"Update on the epidemiology of healthcare-acquired bacterial infections: Focus on complicated skin and skin structure infections","volume":"76","author":"Wilcox","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13017-018-0219-9","article-title":"2018 WSES\/SIS-E consensus conference: Recommendations for the management of skin and soft-tissue infections","volume":"13","author":"Sartelli","year":"2018","journal-title":"World J. Emerg. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.25251\/skin.5.2.7","article-title":"The Global Burden of Skin and Subcutaneous Disease: A Longitudinal Analysis from the Global Burden of Disease Study From 1990-2017","volume":"5","author":"Giesey","year":"2021","journal-title":"Skin"},{"key":"ref_6","unstructured":"(2018). Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 392, 1736\u20131788."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"861115","DOI":"10.3389\/fmed.2022.861115","article-title":"Global Burden of Bacterial Skin Diseases: A Systematic Analysis Combined with Sociodemographic Index, 1990\u20132019","volume":"9","author":"Xue","year":"2022","journal-title":"Front. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"iii35","DOI":"10.1093\/jac\/dkq302","article-title":"Complicated skin and soft tissue infection","volume":"65","author":"Dryden","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1198-743X(16)30095-7","article-title":"Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections","volume":"22","author":"Russo","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/QCO.0000000000000807","article-title":"The role of Gram-negative bacteria in skin and soft tissue infections","volume":"35","author":"Russo","year":"2022","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1093\/cid\/civ528","article-title":"Skin and soft-tissue infections: A critical review and the role of telavancin in their treatment","volume":"61","author":"Cardona","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.2147\/IDR.S172366","article-title":"Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics","volume":"11","author":"Leong","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2165\/11635660-000000000-00000","article-title":"Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections","volume":"72","author":"Lodise","year":"2012","journal-title":"Drugs"},{"key":"ref_14","unstructured":"(2022, December 02). TEFLARO\u00ae (Ceftaroline Fosamil) for Injection for Intravenous Use. Available online: https:\/\/www.rxabbvie.com\/pdf\/teflaro_pi.pdf."},{"key":"ref_15","unstructured":"Pfizer (2022, December 02). Zinforo 600 mg Powder for Concentrate for Solution for Infusion: Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zinforo-epar-product-information_en.pdf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1007\/s40121-022-00712-x","article-title":"International Validation of a Methicillin-Resistant Staphylococcus aureus Risk Assessment Tool for Skin and Soft Tissue Infections","volume":"11","author":"Zasowski","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijid.2019.07.007","article-title":"Risk factors associated with methicillin-resistant Staphylococcus aureus skin and soft tissue infections in hospitalized patients in Colombia","volume":"87","author":"Gualtero","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"282","DOI":"10.5811\/westjem.2013.8.18040","article-title":"Skin infections and antibiotic stewardship: Analysis of emergency department prescribing practices, 2007-2010","volume":"15","author":"Pallin","year":"2014","journal-title":"West J. Emerg. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/cid\/ciaa133","article-title":"Epidemiology, Disposition, and Treatment of Ambulatory Veterans with Skin and Soft Tissue Infections","volume":"72","author":"Rhoads","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1017\/S0950268817001716","article-title":"The rise of methicillin resistant Staphylococcus aureus: Now the dominant cause of skin and soft tissue infection in Central Australia","volume":"145","author":"Macmorran","year":"2017","journal-title":"Epidemiol. Infect."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1093\/ofid\/ofy270","article-title":"Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program","volume":"6","author":"Diekema","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijantimicag.2018.10.026","article-title":"Increase in the prevalence of Panton-Valentine leukocidin and clonal shift in community-onset methicillin-resistant Staphylococcus aureus causing skin and soft-tissue infections in the Rhine-Neckar Region, Germany, 2012\u20132016","volume":"53","author":"Klein","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_23","unstructured":"(2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet, 399, 629\u2013655."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jgar.2021.04.020","article-title":"In vitro activity of ceftaroline and comparators against bacterial isolates collected globally from patients with skin infections","volume":"26","author":"Stone","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.2147\/IDR.S226649","article-title":"In Vitro Activity of Ceftaroline and Comparators Against Staphylococcus aureus Isolates: Results from 6 Years of the ATLAS Program (2012 To 2017)","volume":"12","author":"Zhang","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1429.e1","DOI":"10.1016\/j.cmi.2019.03.023","article-title":"Impact of EUCAST ceftaroline breakpoint change on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from patients with complicated skin and soft-tissue infections","volume":"25","author":"Stone","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1469-0691.12463","article-title":"European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid","volume":"20","author":"Bassetti","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_28","unstructured":"Siddiqui, A.H., and Koirala, J. (2022). StatPearls, StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jgar.2014.02.006","article-title":"In vitro activity of ceftaroline tested against isolates from the Asia-Pacific region and South Africa (2011)","volume":"2","author":"Flamm","year":"2014","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.diagmicrobio.2016.07.012","article-title":"In vitro activity of Ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012-2014","volume":"86","author":"Karlowsky","year":"2016","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jgar.2020.12.013","article-title":"In vitro activity of ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in the Middle East and Africa: AWARE global surveillance programme 2015\u20132018","volume":"24","author":"Karlowsky","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.bjid.2015.08.011","article-title":"Activity of ceftaroline and comparators against pathogens isolated from skin and soft tissue infections in Latin America\u2014Results of AWARE surveillance 2012","volume":"19","author":"Hoban","year":"2015","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.bjid.2013.02.008","article-title":"Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010","volume":"17","author":"Flamm","year":"2013","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13756-020-00829-z","article-title":"Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime-avibactam: A surveillance study from the ATLAS program (2012\u20132016)","volume":"9","author":"Zhang","year":"2020","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_36","unstructured":"ATLAS Surveillance (2022, December 02). Antimicrobial Testing Leadership and Surveillance. Available online: https:\/\/atlas-surveillance.com."},{"key":"ref_37","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2022). Performance Standards for Antimicrobial Susceptibility Testing, CLSI. [32nd ed.]. CLSI Supplement M100."},{"key":"ref_38","unstructured":"European Committee on Antimicrobial Susceptibility Testing (2022, December 02). Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 12.0. Available online: https:\/\/www.eucast.org\/."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1128\/AAC.05186-14","article-title":"Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013","volume":"59","author":"Lob","year":"2015","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/8\/1237\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:20:16Z","timestamp":1760127616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/8\/1237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["antibiotics12081237"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12081237","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]}}}